Meril Life Sciences has introduced the first ever indigenously designed and manufactured transcatheter aortic heart valve (TAVR) – Myval. With this launch, Meril becomes the first Indian company to make transcatheter aortic heart valve replacement (TAVR) therapy commercially available on the world stage. TAVR is an established treatment modality for patients who are at a high risk or unwilling to undergo open heart valve replacement surgery. TAVR is a minimally invasive procedure in which the doctor places a replacement valve into the patient’s native diseased valve via a catheter inserted through the femoral artery (large artery in groin). This is an alternative way to replace diseased valves without undergoing traditional open heart procedure (which some patients may not tolerate well).
Since its inception, Meril has played a leading role in developing and introducing innovative medical technologies. The Myval-TAVR technology has been developed after 6 years of extensive research and is backed by robust bench testing and pre-clinical and clinical data. The Myval TAVR technology has been designed and developed by Meril Life Sciences, headquartered in Vapi, Gujarat, India and has recently received approval for use by Central Drugs Standard Control Organization (CDSCO).
The approval was received on the basis of successful results from a clinical trial done in India. All patients are doing well post procedure and during follow-up. This novel Myval technology is associated with zero new pacemaker implantation rates post procedure (which is an important benefit for the patient already treated for valve replacement). Pacemaker is an additional device that may be placed post TAVR procedure.
“Through the commercialization of this technology, Meril will soon bring the next generation treatment modality to thousands of patients across the country and globally, making India proud of this achievement.”
Vice President-Corporate Strategy,
Meril Life Sciences